Frequently Asked Questions
The rising prevalence of conditions like glaucoma, optic neuritis, and ischemic optic neuropathy due to aging populations, diabetes, and lifestyle changes is a major factor driving growth. As more patients experience optic nerve damage and vision loss, demand grows for specialized treatments. Advancements in drug development and delivery techniques like eye drops, implants, and injections are also fueling expansion by improving efficacy and minimizing side effects.
The COVID-19 pandemic disrupted ophthalmology services, leading to fewer diagnoses and delayed care. Ongoing supply chain disruptions and regional access issues also hamper growth. Moreover, the complex biology of these disorders makes research expensive, while lack of awareness and access to eye care restricts treatment penetration in disadvantaged areas.
The global optic nerve disorders treatment market is expected to reach around $5.4 billion by 2032, growing at a compound annual growth rate of 4.61% from 2024 to 2032.
Advancements in drug delivery methods like sustained-release eye drops, intraocular implants, and targeted injections are showing promise to improve treatment efficacy while minimizing side effects. Furthermore, new therapies derived from stem cell and gene research are emerging as potential ways to repair optic nerve damage and preserve vision over the long term.